Unlock instant, AI-driven research and patent intelligence for your innovation.

Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis

A technology of boric acid and thrombin, which can be used in boron compound active ingredients, blood diseases, cardiovascular system diseases, etc., and can solve problems such as low bioavailability.

Inactive Publication Date: 2009-03-25
TRIGEN
View PDF32 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Similarly, drugs with low levels of bioavailability (only a small portion of the administered active agent is absorbed) are generally unacceptable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis
  • Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis
  • Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0447] The synthesis of embodiment 1-TRI50D

[0448] Step 1: Z-DIPINB

[0449] Program A

[0450] Add 17.8g (732.5mmole) of magnesium turnings, 0.1g (0.4mmole) of iodine and 127ml of anhydrous tetrahydrofuran and heat to reflux. 15 ml of a solution of 66 g (608 mmole) of 1-chloro-3-methoxypropane in 185 ml of anhydrous tetrahydrofuran are then added and stirred at reflux until a vigorous reaction occurs. After the initial exotherm had subsided, the 1-chloro-3-methoxypropane solution was slowly added to maintain a gentle reflux until all the magnesium was consumed. After the reaction was complete, the reaction mixture was cooled to ambient temperature, and a solution of 64.4 g (620 mmole) of trimethylborate in 95 ml of anhydrous tetrahydrofuran was slowly added; the latter solution was cooled to below 0° C. During its warming, the reaction mixture must be added very slowly to keep the temperature of this solution below 65°C. After the addition was complete, the reaction...

Embodiment 2

[0467] Synthesis of embodiment 2-TRI50D (diethanolamine adduct of TRI 50C)

[0468]The starting material used in this example was the TRI50b solution obtained in Example 1 (Z-DIPIN). This solution was directly subjected to the synthesis of TRI50d without further purification. The Z-DIPIN solution in t-BME (containing 7.0 g (11.5 mmole) (R, S, R) TRI50b, calculated based on the HPLC results of Z-DIPIN) was evaporated to dryness, and the evaporation residue was dissolved in 80 ml diethyl ether middle. 1.51 g (14.4 mmole) of diethanolamine were added and the mixture was heated at reflux for at least 10 hours, during which time the product precipitated. The suspension was cooled to 5-10°C, and the residue washed with diethyl ether was filtered.

[0469] To improve chirality and chemical purity, the wet filter residue (7 g) was dissolved in 7 ml of dichloromethane, cooled to 0-5°C, the product was precipitated by adding 42 ml of diethyl ether and filtered. The isolated wet pr...

Embodiment 3

[0472] The preparation of the sodium salt of embodiment 3-TRI50C

[0473] 1.5 kg (2.5 mole) of TRI50d obtained in Example 2 was dissolved in 10.5 L of dichloromethane. 11 L of 2% hydrochloric acid was added and the mixture was stirred at room temperature for up to 30 minutes (optionally about 20 minutes). A precipitate formed in the organic phase. After stirring, the layer was allowed to settle and separate. The aqueous layer was washed two more times with 2.2 L of dichloromethane. The combined organic layers were washed with a solution of 625 g ammonium chloride in 2.25 L water. (The pH of the ammonium chloride buffered aqueous extract is in the range of about pH 1-2 to about pH 4-5, since strongly acidic conditions can cleave peptide bonds). The organic phase was dried over magnesium sulfate, filtered and the filtrate was evaporated to dryness. Free boronic acid analysis (by the RPHPLC method of Example 28 at room temperature for up to 30 minutes (optionally about 20 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
Login to View More

Abstract

Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.

Description

[0001] This application is a divisional application of Chinese patent application 03821390.7 filed on September 9, 2003, entitled "Borate and its application in the treatment of thrombosis". technical field [0002] The present invention relates to pharmaceutically useful products derived from organoboronic acids. The invention also relates to the use of each member of the aforementioned class of products, to their formulation, to their preparation, to their synthetic intermediates and to other subjects. [0003] The invention further relates to oral pharmaceutical formulations containing said products. Background technique [0004] boric acid compound [0005] It has been known for some years that boronic acid compounds and their derivatives such as esters have biological activity, in particular as protease inhibitors or substrates. For example, Koehler et al., Biochemistry 10:2477, 1971, reported that 2-phenylethaneboronic acid inhibited the serine protease chymotrypsin ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07F5/02A61K31/69A61P9/10A61P7/02
Inventor 戴维·乔纳森·玛奇马克·多尔曼索菲·玛丽·库姆-马泽勒约翰·约瑟夫·戴德曼安东尼·詹姆斯·肯尼迪桑贾伊·库马尔·卡卡尔
Owner TRIGEN